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of iliac crest donor site pain
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Background: The harvest of iliac crest bone grafts (ICBG) is associated with relevant donor site pain, but may be
lowered by the application of lidocaine loaded on biodegradable, hemostatic putty for sustained local analgesic
release. The goal of this double-blind controlled trial was to assess the efficacy of adding lidocaine to a hemostatic
putty (Orthostat ™) to treat donor site pain following harvest of ICBG in foot and ankle procedures.
Methods: After ICBG harvest during a foot and ankle procedure, the resulting bone defect was either filled with
Orthostat™ (n = 7) or with the same hemostatic putty loaded with lidocaine (Orthostat-L™, n = 7). During the first 72
postoperative hours, donor site and surgical site pain were managed by patient controlled morphine delivery and a
peripheral nerve block. Donor site pain was periodically quantified on a Visual Analog (VAS) and a Wong Baker
FACES scale. Pain scores were plotted over time to calculate the area under the curve (AUC) to quantify the overall
pain experienced in specific time intervals.
Results: Orthostat-L™ significantly reduced donor site pain over the first 12 hours postoperatively as evidenced by a
significant decrease of the AUC in both VAS (p = 0.0366) and Wong Baker FACES pain score plots (p = 0.0024).
Cumulated morphine uses were not significantly decreased with Orthostat-L™.
Conclusion: The addition of lidocaine to a hemostatic putty offers a significant ICBG donor site pain reduction over
the first 12 postoperative hours.
Trial registration: ClinicalTrials.gov NCT01504035. Registered January 2nd 2012.Background
Cortical autologous iliac crest bone grafts (ICBG) are
widely used in orthopedic surgical procedures [1], such as
open wedge osteotomies [2-4], interposition arthrodeses
[5,6] and bone defects. Autologous bone grafts display
excellent biological properties – osteoconductivity [7,8],
osteoinductivity [9], and potentially osteogenicity [10],- plus
favorable biomechanical characteristics [11], and are con-
sidered the gold standard despite the abundance of allo-
genic and synthetic substitutes available [12]. However,
these favorable characteristics have to be juxtaposed with
the risk of associated donor site morbidity, which may be* Correspondence: muelleram@uhsb.ch
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reproduction in any medium, provided the orclinically relevant in approximately 5% of patients, with
values up to 30% in some reports [13-18].
Patients undergoing ICBG harvest often experience sig-
nificant post-surgical bleeding [14] and pain [17] at the har-
vest site and may rarely sustain more severe complications
including fractures [16], arteriovenous fistula [14], nerve
injuries [15] and abdominal wall hernias [19]. The adminis-
tration of hemostatics in combination with local anesthetics
has been proposed to manage pain and bleeding. However,
local anesthetics may clear rapidly from the harvest site,
potentially causing systemic toxicity and reducing duration
and effectiveness of postoperative analgesia [20].
These considerations prompted the incorporation of lido-
caine into a biodegradable hemostatic putty (Orthostat™
currently marketed as Hemasorb™) to locally provide
anesthetic to the surgery site (Orthostat-L™). The Orthostat™
putty is composed of a polyvalent salt of a high molecularLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Müller et al. BMC Musculoskeletal Disorders 2014, 15:415 Page 2 of 7
http://www.biomedcentral.com/1471-2474/15/415weight carboxylic acid, an alkyl benzopyranol ester and
Vitamin E which enables a continuous release of lidocaine.
Orthostat-L™ additionally comprises lidocaine at a concen-
tration of 16% of its dry weight. In a previous in-vitro and
animal study, lidocaine was released from the putty in a
exponential fashion with a half-time of approximately 6–8
hours. [21].
With the addition of Lidocain to Orthostat, pain control
may be provided by two mechanisms. The hemostatic
component may decrease the formation of irritating sub-
periostal hematomas, while the continuous release of
lidocaine may decrease pain perception at the periosteal
level.
In animal studies, the application of Orthostat-L™
resulted in a dose dependent, sustained analgesia in
rats over a duration of two to three days with no evidence
of systemic toxicity [21-23]. However, to our know-
ledge no studies have been performed to confirm this
in humans.
It was the primary objective of this study to compare the
analgesic effectiveness of a lidocaine loaded hemostatic putty
(Orthostat-L™) with a lidocaine deficient putty (Orthostat™),
defined as visual analog (VAS) and Wong Baker FACES
scale outcomes, in a random sample of patients undergoing
ICBG harvest for foot and ankle procedures. We hypothe-
sized that the addition of lidocaine to the putty would
provide significantly better pain control in the early post-
operative period. For the purpose of this study, we
defined “early postoperative” as an observation period
of 72 hours during which we searched for differences in
reported pain.
As a second objective, we aimed to test if, after the
administration of the lidocaine loaded hemostatic putty,
peripheral blood licocaine levels would stay below the
threshold for liver toxicity of 6 mg/l.Methods
Study design
This study was designed as a prospective, comparative,
active-controlled, double-blind trial of the analgesic
effectiveness of Orthostat-L™ (experimental group) with
Orthostat™ (active control) in patients undergoing iliac
crest bone graft (ICBG) harvest. The main outcome
measurement was pain measured on a VAS and Wong
Baker scale. We aimed at being able to detect an at least
10% ± 5% difference between two independent groups in
the cumulative VAS scores within the early postoperative
time period with a power of no less than 90% and a two-
tailed alpha of 5% . This is consistent with an effect size
of 2, thus requiring a total sample size of 14, or 7 per
group, to reach a power of 90%. Such a sample size
would still allow detecting a sample size of 1.5 without
less than at least 80% power.Study subjects
From May to July 2008, we enrolled 14 patients undergo-
ing foot and ankle surgical procedures with the use of a
structural iliac crest bone graft. Patients who were be-
tween 18 and 71 years old and capable of completing a pa-
tient administered analgesia (PCA) device and who had
given their written informed consent were included in the
study. Patients with previous ICBG harvest, serious med-
ical conditions including liver and heart failure, bleeding
diathesis, hypersensitivity to lidocaine or to components
of the hemostatic putty or any mental (dementia/psychi-
atric disorder) impeding their cooperation in the postoper-
ative evaluations were excluded. Upon inclusion, patients
were randomly allocated to the Orthostat™ or Orthostat-L™
group. There were seven patients in each group. Patients as
well as all medical staff were blinded to which product the
patient received.
As a result of the random allocation, there were seven
patients in each group. Table 1 lists the demographic
characteristics of patients allocated to the Orthostat™
and Orthostat™-L group.
The study was conducted in accordance with the
current version of the Declaration of Helsinki and under
the laws and regulations enforced by the local ethics
committees. This trial was registered in ClinicalTrials.
gov (registry number: ClinicalTrials.gov NCT01504035,
registered January 2nd 2012) and approved by the local
ethical committee (EKBB registry number 14/08).
Application of a continuous popliteal sciatic nerve block
Prior to induction of anesthesia, a board certified anaes-
thetist (RZ) administered a peripheral nerve block in the
popliteal fossa proximal to the surgical site. Blocks were
performed with 20–30 ml of mepivacaine 1.5% and bupi-
vacaine 0.5%. After injection a 20G catheter was inserted
for continuous postoperative sciatic nerve block with ropi-
vacaine 0.2%, using an elastomer pump with a flow rate of
6-10 ml/h.
Iliac crest bone graft (ICBG) harvest and application of
Orthostat™/Orthostat-L™
Upon exposure and preparation of the primary surgical
site at the foot and ankle, the same surgeon (VV) obtained
an iliac crest bone graft in the following manner. A skin
incision was made over the anterolateral aspect of the
iliac crest. The aponeurosis of the external oblique was
exposed and incised. The iliac crest was exposed sub-
periosteally, and a tricortical ICBG was obtained with
an oscillating saw. The size of the graft was adapted to
the structural defect at the foot and ankle to be bridged
but was not larger than 3 cm × 1 cm × 2 cm (6 cm3).
The graft dimensions were measured and the donor site
was dried with sterile gauzes. Then either Orthostat™ or
Orthostat-L™ was administered to the exposed bone
Table 1 Patient demographics and intraoperative data (Data presented as mean ± SD)
Orthostat-L™ (n = 7) Orthostat™ (n = 7) P-value
Gender 4 Females, 3 Males 3 Females,4 Males
Mean age (years) 42.6 ± 10.5 51.0 ± 16.9 0.248
Mean duration of Surgery (minutes) 169.4 ± 53.3 140.9 ± 38.5. 0.273
Graft size (cm3) 4.0 ± 2.9 3.4 ± 1.9 0.681
Putty amount (grams) 4.3 ± 1.2 4.3 ± 0.8 0.999
Mean time to hemostasis after putty administration (seconds) 24 ± 11 37 ± 37 0.392
Intraoperative blood loss at the ICBG harvest site (ml) 15 ± 8 15 ± 5 0.999
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terial filling ICBG harvest site was flush with the bone
surface. The amount of Orthostat™/Orthostat-L™ was de-
termined by the number of 2 g portions applied to the
harvest site and by weighing the leftover of the last por-
tion used. The time from the end of putty application to
complete hemostasis at the donor site was recorded and
judged to be complete when there was no active bleeding
noted by the surgeon. In addition the aspirated blood
volume from the iliac crest was measured and recorded
for blood loss. The wound was then closed in layers. No
blood drain was inserted at the iliac crest harvest site.
Outcome assessment - donor site pain
Patients were closely followed every four hours within the
first 72 hours of Orthostat™/Orthostat-L™ administration
by blinded assessors. The pain level at the pelvic harvest
site was rated according to the VAS score and Wong-
Baker FACES Pain Rating Scale. VAS scores were mea-
sured on a continuous scale ranging from 0–100 mm. The
Wong Baker scale ranged from 0 to 5 points, with the
verbal anchors “no pain” to “worst pain”. The VAS and
Wong-Baker pain scores for each patient were plotted
over time. The area under the curve (AUC) was calculated
to represent the cumulative pain experienced within a
specific time period. Since the surgical site pain from the
lower extremity was addressed by a continuous sciatic
nerve block, any pain experienced by the patient was
related to iliac crest donor site pain. In case of any
dysfunction of the sciatic block, the level of surgical site
pain had to be recorded in the protocol.
Additional postoperative pain control was provided for
all patients using patient controlled analgesia pumps
(PCA) loaded with morphine. The cumulative dose of
morphine used within the first 72 h after surgery was
quantified.
Outcome assessment - serum Lidocaine levels and adverse
events
Serum lidocaine levels were measured after the adminis-
tration of the peripheral nerve bloc (baseline) and at 2, 4,
8 12, 48, and 72 hours after the application of the puttyusing high performance liquid chromatography. Blood
samples for serum lidocaine measurements were obtained
from the basilic vein of the ipsi-contralateral arm and
analysed immediately. The formation of a local hematoma
at the iliac crest harvest site was assessed by ultrasound
performed after 48–72 hours. After discharge from the
hospital, patients were followed up at 14 and 30 days after
surgery. During these follow-up visits, any adverse event
such as prolonged pain, hematoma, herniation etc. at the
pelvic harvest site was recorded.
Statistical analysis
Two-tailed t-tests for independent samples were used to
compare cumulative PCA, bleeding time, total blood
loss, and graft size across treatment groups. Continuous
variables including VAS pain scores at different time
points as well as the area under the curve for VAS and
Wong Baker scores were tested using repeated measure
ANOVA. For the 16 hours’ time point, more than 20%
of VAS and Wong Baker FACES measurements were
missing and thus the time point had to be dropped.
Discontinuous variables including Wong - Baker scores
were analysed using Fisher’s exact test with Bonferroni
adjustments for multiple measurements. Results are
given as mean ± SD. An alpha of 5% was considered
significant. All analyses were done using intercooled
STATA 10 (Stata Corp LP, College Station, TX).
Results
Intra-operative data
As shown in Table 1, the duration of surgery, intraopera-
tive blood loss and time to hemostasis after putty adminis-
tration, as well as graft sizes and amount of putty used
were not significantly different between Orthostat-L™ and
Orthostat ™ (control) group.
Analgesic effectiveness of Orthostat-L™ - donor site pain
There were no cases of sciatic block dysfunction. All
pain recorded was related to the iliac crest donor site.
Subjects treated with Orthostat-L™ showed a signifi-
cantly improved area under the curve (AUC) of the
VAS score (AUCvas) as compared to Orthostat™ from 1
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p = 0.036) (Figure 1). From 12 to 24 hours the control
scores decreased towards baseline and differences between
Orthostat-L™ and Orthostat™ were no longer statistically
significant (AUC VAS 64 ± 62 vs 87 ± 79, p = 0.281). In the
repeated measure ANOVA of all time points individually,
there was no significant difference across groups VAS
score (p = 0.3644) over the total follow-up.
For the Wong-Baker FACES Pain Rating Scale there
was a significantly better outcome for Orthostat-L™
compared to Orthostat™ for the AUC for the first
12 hours (AUC Wong-Baker 6 ± 6 vs. 15 ± 15, p = 0.0024
(Figure 2)) suggesting a beneficial early effect. Between 12
and 24 hours postoperatively as well as beyond 24 hours,
as the control scores returned to baseline, the AUC
obtained from Wong-Baker FACES Pain Rating Scale was
not significantly different across groups (p = 0.999 and
p = 0.1772, respectively), suggesting that the early effect
equilibrates by the third postoperative day. There was no
significant difference across groups regarding Wong-Baker
FACES scores (p = 0.3544) at individual time points. There
was no significant difference in cumulative PCA delivered
morphine dose at 12 h (p = 0.267), 24 h (p = 0.717), or
72 hours postoperatively (p = 0.109) between the two
groups.Safety of Orthostat-L™ - Lidocaine levels and adverse
effects
In the Orthostat-L™ group, the serum levels of lidocaine
peaked at 8 hours remained elevated until 40–48 hours.
At all time points, lidocaine levels stayed well below
toxic levels of 6 mg/l. The mean lidocaine levels in the
peripheral blood was significantly higher (p = 0.022) for
the Orthostat-L™ group than the control group (Figure 3).
There were no serious adverse effects experienced by
subjects in the study. There was one case of seroma at
the graft site in the intervention group that became
evident prior to discharge on the fifth day after surgery.Figure 1 Postoperative VAS pain scores recorded at periodical time inIt required manual expression of the serous fluid to
resolve. There were no complications in the control
group (p = 0.2994).
Discussion
Iliac crest bone graft harvesting is associated with a donor
site morbidity of up to 30% [13,14,16]. Fortunately, major
complications occur only rarely. However, patients fre-
quently experience significant pain at the harvest site after
ICBG harvest [17]. Standard pain management includes
use of opioid analgesics, which may cause respiratory
depression [24], nausea, vomiting or decreased gastro-
intestinal motility [25], and thus may temporarily worsen
the patient’s condition and result in unfavorable outcomes
and extended hospital stays with increased costs. Hence,
reduction of postoperative pain at the harvest site will
reduce or eliminate the comorbidities associated with
use of systemically applied analgesics such as opioids.
In this study we evaluated the effectiveness of a lidocaine
loaded hemostatic putty (Orthostat-L™) as compared to a
lidocaine deficient putty to lower iliac crest donor site pain.
Our study has potential limitations. Our sample was
small, aiming for a between group difference of 10% ± 5%,
and a larger study would be capable of detecting a smaller
difference than that with statistical significance. However,
the statistical significance of such a smaller difference
must be put into relation with its clinical meaning, which
might be questionable. Also, experiencing postoperative
pain and response to analgesic medication has consider-
able inter-individual variability. Another potential short-
coming of a small sample size is a potentially higher risk of
bias due to differential distribution. However, the enrolled
patients were not significantly different in demographics
and duration of procedure undergone, and systemic disease
and lidocaine-related issues were exclusion criteria in our
study. Hence it is not likely that our data are affected by
substantial bias.
In our study, Orthostat-L™ significantly reduced cumula-
tive VAS and Wong Baker FACES pain scores at the harvesttervals after putty administratioon.
Figure 2 Postoperative Wong-Baker FACES pain scores.
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scores in the control group began to return to baseline
values. Nonetheless, pain scores in the Orthostat-L™-group
continued to be lower compared to the Orthostat™-
group, however, without statistical significance. The
limited duration of significant pain relief provided by
Orthostat-L™ may be explained by the fact that the control
subjects returned to low pain levels just after 12 hours
and by 20 hours after putty administration. Thus, there
was no relevant pain for Orthostat-L to mitigate after this
time period. In addition, the effects of lidocaine could
have been also been altered by a local inflammatory
response due to the surgical intervention and, additionally,
to the putty. It has been postulated that inflammatory cell
released peroxynitrite could decrease the effect of local
anesthetic effects [26,27]. Our data do not suggest that the
duration of pain relief was restricted by limited lidocaineFigure 3 Postoperative Serum lidocaine levels.release from the putty. Lidocaine levels remained elevated
in the Orthostat-L™ group even beyond 36 hours which
was in fact in line with previous in vitro results [21]. Thus,
Orthostat-L™ showed a much more favorable drug elution
profile as compared to single administrations of local
anesthetics. After single infiltration of the iliac crest
with local anesthetics, plasma levels peak within 20–100
minutes and rapidly decrease thereafter [20].
Throughout the study, we could not detect a signifi-
cant difference regarding cumulative PCA use between
the two study groups. This result may be interpreted in
two ways: First, our study was primarily powered to
detect significant differences regarding cumulative VAS
scores and not narcotic use. Second, Ip et al. [28]
showed in a systematic review that there are determi-
nants of postoperative pain medication use which are
independent from VAS rated pain. These parameters
Müller et al. BMC Musculoskeletal Disorders 2014, 15:415 Page 6 of 7
http://www.biomedcentral.com/1471-2474/15/415include anxiety and behavioral abnormalities which were
not assessed in our study. We can therefore not exclude
any confounding by these psychological factors.
Our data do not suggest that the duration of pain
relief was restricted by limited lidocaine release from the
putty. Lidocaine levels remained elevated in the
Orthostat-L™ group even beyond 36 hours which was in
fact in line with previous in vitro results [21]. Thus,
Orthostat-L™ showed a much more favorable drug elution
profile as compared to single administrations of local
anesthetics. After single infiltration of the iliac crest
with local anesthetics, plasma levels peak within 20–100
minutes and rapidly decrease thereafter [20].
In terms of safety, our study was able to demonstrate
that serum lidocaine levels remained well below the level
of toxicity (6 mg/l). The maximum serum lidocaine level
noted in our study was 2.1 mg/l and was registered after
4 hours. We noted the occurrence of one seroma in the
Orthostat-L™ group. This complication may be rather
interpreted as a minor donor site complication and not
as an adverse event directly related to the local drug
application. Such minor complications may occur with a
frequency of 10-15% [14,16].
Previous studies have already suggested the installation
of local anesthetics to reduce donor site pain at the iliac
crest [20,29-35]. The proposed techniques vary from
local infiltration at the time of surgery [20,32,35] to
intermittent [30] or continuous [31,33,34] administration
using indwelling catheters. Similar to our study, single
or intermittent administration of local anesthetics at the
harvest site significantly reduced donor site pain 12–24
hours postoperatively [20,30,35]. Serum concentrations
also stayed below the toxic level [20]. Continuous
administration could increase the duration of pain relief
to up to 48 hours in one study [34] while another study
could not demonstrate this effect [31]. Study results
were also very conflicting regarding the effect on local
anesthetics on the intake of narcotics in the postopera-
tive period. Some studies showed that the application of
local anesthetics at the iliac crest could significantly
decrease the postoperative opioid demand [30,34], while
others could not reproduce these results [20,31]. How-
ever, the aforementioned studies contained heteroge-
neous sample groups and showed variable confounders
or biases. Most importantly, these studies did not elim-
inate the surgical site pain. Pain perception at one side
increases anxiety and thus alters the pain perception
across other body sites [36]. Accordingly, Morgan et al.
[31] could demonstrate in their study a significant
correlation between recipient and donor site pain. How-
ever, only few studies incorporated the level of pain at
the surgical site in the analysis and interpretation of
their data [20,31,34]. Our study could avoid these con-
founding effects since surgical site pain was continuouslyeliminated by the popliteal blocks. Thus, pain relieve at
the donor site can more directly be attributed to the
effectiveness of Orthostat-L™.
When comparing Orthostat-L™ with local anesthetics,
it must be considered that that Orthostat-L™ is also a
hemostatic agent. In contrast to local anesthetics,
Orthostat-L™ may therefore additionally help to prevent
irritating subperiosteal hematomas, which further con-
tribute to donor site pain. Nevertheless, these specula-
tions on the superior effectiveness of Orthostat-L™ to
reduce donor site pain needs clarification in future ran-
domized controlled trials.
Conclusions
A bioresorbable hemostatic putty with lidocaine, as
Orthostat-L™ has significant effectiveness in controlling
pain experienced within 12 hours after iliac crest bone
graft harvesting compared to a putty without lidocaine, as
Orthostat™. We found no evidence for systemic toxicity or
an increase in risk of adverse effect using a lidocaine based
putty.
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